|Year : 2020 | Volume
| Issue : 3 | Page : 164-169
Vitamin B12 and Folic Acid in Depression and Anxiety: A Pilot Study
Department of Psychiatry, Faculty of Medicine, Uskudar University, Istanbul, Turkey
|Date of Submission||04-Nov-2020|
|Date of Decision||11-Nov-2020|
|Date of Acceptance||16-Nov-2020|
|Date of Web Publication||25-Dec-2020|
Assistant professor, Psychiatry Department, Uskudar University, Faculty of Medicine, Istanbul
Source of Support: None, Conflict of Interest: None
Background: The association between nutrition and mental diseases has been extensively studied. Vitamin B12 and folic acid are the main vitamins in the development of the central nervous system. This study aimed to investigate the relationship between vitamin B12 and folic acid levels with depression and anxiety. Methods: A total of 150 patients (77 with anxiety and 73 with depression) between 18 and 79 were enrolled. The initial mood state was evaluated using Beck's Depression Inventory-II (BDI-II) and Beck's Anxiety Inventory (BAI) for the presence of depression and anxiety, respectively. Venous blood samples were collected after overnight fasting and vitamin B12 and folic acid levels were measured. Results: Serum concentrations of folic acid were significantly lower in patients with depression than those with anxiety (p=0.04). Substantially higher vitamin B12 levels were described in men than females counterparts with severe depression (p=0.049). Additionally, there was a significant inverse correlation between folic acid levels and Beck's inventory score among patients with severe depression (r=-0.250, p=0.049). Conclusion: Serum levels of vitamin B12 and folic acid could be used as markers that assess anxiety and depression's therapeutic efficiency.
Keywords: Anxiety, Beck's Depression Inventory score, depression, folic acid, mood disorders, Vitamin B12
|How to cite this article:|
Erensoy H. Vitamin B12 and Folic Acid in Depression and Anxiety: A Pilot Study. J Neurobehav Sci 2020;7:164-9
| Introduction|| |
Depression and anxiety are considered the most prevalent mental diseases, resulting in the loss of the affected individuals' socioeconomic productivity. Therefore, the effective treatment of these disorders should be included as coherent chronic disease management. During the past decade, various epidemiological studies have been conducted to investigate the relationship between nutritional patterns and individuals' mental status so that dietary habits have been suggested as an underlying cause to onset the psychiatric symptoms. In this regard, “nutritional psychology” mainly focuses on nutrition or a single nutrient on mood disorders, including depression and anxiety. The most frequent nutritional-related deficiencies in mental diseases include ω-3 fatty acids, Vitamin B family, mineral elements, and amino acids, which are the neurotransmitters precursors in the nervous system.
Vitamin B12 and folic acid as the main water-soluble vitamins play a crucial role in the central nervous system (CNS) development and health. Vitamin B12 and folic acid have a shared metabolism so that the deficiency in one vitamin impairs the other vitamin function. There are two main mechanisms proposed for the role of Vitamin B12 and folic acid in CNS development: (i) the role of these vitamins in the myelination process and (ii) methionine synthesis from homocysteine (h-Cys) as a crucial amino acid in neural tube formation and development. Moreover, folate deficiency increases h-Cys and decreases S-adenosylmethionine, causing methylation capacity reduction and finally alters neurotransmitter synthesis.
However, the role of these vitamins in depression and anxiety management remains controversial. It has been reported that patients with low folate levels show a mean longer time for depression improvement compared to individuals with normal folate levels. In addition, the relapse rate was also higher in patients with low folate levels. Furthermore, increases in the blood folate levels during antidepressive treatment significantly improved the Hamilton depression scale score. A higher blood folate concentration was also observed after the treatment in “responding” than that of “nonresponding” patients. Sepehrmanesh et al. reported that folic acid supplementation in major depressive disorder improves the antidepressant response in these patients be considered as a complementary treatment. However, Walker et al. showed no significant improvement in depressive symptoms following folic acid administration.
On the other hand, recent literature has also indicated the link between Vitamin B12 deficiency and depression. High serum Vitamin B12 levels have reported being associated with satisfactory treatment outcomes; however, high h-Cys levels, which is usually observed in folate/Vitamin B12 deficiency in depressive patients, are typically associated with inadequate response to antidepressant therapy., Syed et al. reported a significant improvement in depressive symptoms after Vitamin B12 supplementation combined with antidepressants. In contrast, in a 2-year Vitamin B12 supplementation study, no significant improvement in depressive symptoms was observed in adult patients. However, a beneficial effect on health-related quality of life was reported in this research. Vitamin B12 and folic acid supplementation also have improved the Hamilton depression and anxiety scores in human immunodeficiency virus-positive patients.
According to a recent report, the Vitamin B12, not the folic acid concentrations, was inversely correlated with the severity of depression. This study examined the association between the serum concentrations of these two nutrients and the severity of mood disorders observed in individuals of both sexes over a wide range of ages.
| Materials and Methods|| |
Ethics committee approval
The non-interventional research ethics committee approved this study at Uskudar University (Code: 61351342-/2019-80; date: 27.02.2019).
Seventy-seven patients with anxiety and 73 patients with depression referred to the Neuropsychiatry Clinic at Uskudar University were screened and enrolled in this study from March to December 2018. The patients with overlapping characteristics of depression and anxiety were excluded. History of serum Vitamin B12 and folic acid altering diseases such as hepatic dysfunction, renal disorders, and diabetes mellitus or current use of the mentioned vitamins' supplements was also considered as exclusion criterion.
The psychiatric examination of the patients was done using Beck's Depression Inventory-II (BDI-II) and Beck's Anxiety Inventory (BAI) for the presence of depression and anxiety, respectively, and the scales were validated in Turkey., These tests contained 21 multiple choice questions with a maximum score of 3 for each item. The patients performed the tests under the supervision of a psychologist. BDI-II scores ≤9 were considered as no depression. Depression severity was also categorized as mild (BDI-II 10–15), moderate (BDI-II 16–23), and severe (BDI-II ≥24). BAI scores of <15 were also considered as unfavorable for anxiety; mild (BAI scores 16–22), moderate (BAI scores 23–42), and severe (BAI scores ≥43). Patients with BDI-II ≤9 and BAI <15 scores were excluded from the study.
Sampling and biochemical assay
Serum folic acid and Vitamin B12 were measured after overnight fasting in all subjects using a Roche Cobas e411 (Mannheim, Germany) instrument. Low serum Vitamin B12 (<200 pg/ml) and folic acid (<2.2 ng/ml) levels were considered as deficiency.
Sample size determination and statistical analysis
The sample size was determined to establish a power of 80% and a confidence interval of 95%, using the following formula: sample size = Z1−α/22 × P−(1 − P)/d2. Data were analyzed using the statistical package for social sciences (SPSS® version 23, IBM Inc., Chicago, IL, USA). The numerical variables were expressed as mean ± standard deviation. If a normal distribution was not detected with the Kolmogorov–Smirnov test, the variables were analyzed with a nonparametric Kruskal–Wallis test to compare the mean differences between groups. In addition, bivariate correlation analysis was performed to assess the association between clinical variables and Vitamin B12 or folic acid levels. P < 0.05 was considered statistically significant.
| Results|| |
Demographics and general characteristics of participants
There were 77 patients with anxiety and 73 patients diagnosed with depression. The median, range, and proportion of Vitamin B12 and folic acid deficient individuals are presented in [Table 1]. Vitamin B12 and folic acid concentrations were significantly lower in subjects with depression than those with anxiety (P = 0.04). However, there were no differences in serum concentrations of Vitamin B12 and folic acid in patients with anxiety or depression when the subjects were grouped according to their age [Table 2]. An analysis of gender subgroups revealed that Vitamin B12 and folic acid were similar between the patients of both sexes. However, men with depression had marginally higher levels of Vitamin B12 than female patients with depression (P = 0.049) [Table 3].
|Table 2: Comparison of biochemical indices between anxiety and depression groups and subgroups|
Click here to view
|Table 3: Comparison of biochemical indices between male and female individual through anxiety and depression subgroups|
Click here to view
Correlation of Vitamin B12 and folic acid concentration with Beck's depression/anxiety inventory scores
As it is presented, a significant negative correlation was observed between folic acid levels and BDI-II in severely depressed patients (r = −0.250, P = 0.049). Univariate association and correlation between Vitamin B12 and folic acid levels and Beck's inventory scores for depression and anxiety are presented in [Table 4].
|Table 4: Correlation of biochemical parameters with anxiety and depression beck degree|
Click here to view
| Discussion|| |
The study aim was to evaluate the association of anxiety and depression with the levels of Vitamin B12 and folic acid. We described higher levels of Vitamin B12 in depressed males than female subjects with the same mood disorder. A lower level of serum folic acid in the depression group was observed compared to the anxiety group. Moreover, correlation analysis showed a significant negative correlation between folic acid levels and Beck's inventory score in severely depressive patients. This finding is similar to the results of a study conducted by Sánchez-Villegas et al.
Vitamin B12 and folic acid are critical for the development and the proper function of the nervous system in humans. Conducted studies during the last decades have indicated an association of these vitamins' deficiencies with psychological symptoms, such as depression and cognitive impairment.,
In an experimental study, Lerner et al. compared the serum concentations of Vitamin B12 and folic acid in 224 newly diagnosed psychiatric patients and healthy controls in an Israelian population. The results showed no significant differences between Vitamin B12 levels within groups. In contrast, folate serum level was significantly higher in controls compared to patients with mood disorders. Moreover, a significant positive correlation was also observed between low folic acid levels and depression, consistent with our data. In a recent cross-sectional large cohort study on 7963 healthy Israelian individuals aged 18–65 years, Margalit et al. observed a significantly lower level of serum Vitamin B12 in men compared to the women. On the other hand, most of the examined population belonged to a higher socioeconomic class and may affect the external validity of the study by Margalit et al. In addition, Vitamin B12 deficiency prevalence in men was also higher. Nutritional, hormonal, and social factors may partially clarify the obseved differences between the two genders.
Single-nucleotide polymorphism in the gene fucosyltransferase two has been associated with Vitamin B12 absorption and serum level. Among the healthy population, men are susceptible to Vitamin B12 deficiency. This can be explained by neither diet habits nor estrogen effects. Genetic variations involved in Vitamin B12 homeostasis are therefore hypothesized to play a role. The lower serum Vitamin B12 level in female severe depressive individuals in our study may explain the importance of this vitamin in mood disorders. Although the serum levels of Vitamin B12 levels were low, they did not reach a “deficient” state in studied subgroups.
Based on the previous studies' reports, folic acid's role in mood disorders, including depression, seems to share a higher degree of importance. In a cross-sectional analysis was carried out by the National Health and Nutrition Examination Survey data, a noncausal association was observed between various serum vitamins (including Vitamin B12 and folate) concentrations and depression in 2791 individuals. In this study, folate and Vitamin B12 concentrations were also identified to be correlated with depression in the females.
In a double-blind, randomized controlled trial, depression scores were significantly reduced following combined treatment with 20 mg citalopram plus 2.5 mg folate when compared to controls. Furthermore, 73% of the patients receiving folate supplements had a favorable response to citalopram, while only 40% of the patients in the control group demonstrated a favorable outcome to the treatment. The lower levels of folate in depressed patients and the negative association between folate and severe depression in our study may also confirm this vitamin's importance in mood disorders, especially depression.
Passen et al. also compared the effects of 5'-methyltetrahydrofolate (50 mg/day) and trazodone (100 mg/day) in addition to standard psychotropic medication on depression and cognitive status in a double-blind design for 8 weeks in an Italian population. In this study, a significant decrease in the Hamilton Depression Rating Scale was observed in patients supplemented with folate than the baseline, and the trazodone treated group after 4 and 8 weeks of intervention.
The association of low folate levels and poor response to selective serotonin reuptake inhibitors (SSRIs) has also been previously described in significant depression., Papakostas et al. reported a higher efficacy of adjunctive 15 mg/day L-methyl-folate in combination with SSRI therapy compared to the placebo group for 60 days in both primary and secondary depression symptoms' improvement. Similar results have also been reported from the United States.
The limitations of our study include (i) relatively small study population, a higher population may exert more confident results, particularly in anxiety patients; (ii) lack of a healthy control group; and (iii) the cross-sectional data. Other factors, including the duration of the Vitamin B12 and folic acid deficiency, duration of psychiatric symptoms, lifestyle, and genetic variations, may also explain these relationships. Thus, further studies are still needed to examine the causal pathways between these vitamin deficiencies and mood disorders.
| Conclusion|| |
Based on our findings, Vitamin B12 and folic acid measurement may help the physicians for efficient anxiety and depression management. In this regard, folic acid seems to be more critical in mood disorder improvement outcomes and is suggested to be evaluated more carefully. Moreover, regarding the fact that the mean level of Vitamin B12 and folic acid was within typical values in this study, the need for treatment when no deficiency exists may be beneficial for better treatment outcomes.
The author gratefully acknowledges the assistance of laboratory staff and the patients who collaborated with this study. The author declares no conflict of interest.
Patient informed consent
Informed consent was obtained.
Ethics committee approval
This study was approved by the non-Interventional Research Ethics Committee at Uskudar University (Code: 61351342-/2019-80; date: February 27, 2019).
Financial support and sponsorship
No funding was received.
Conflicts of interest
There is no conflict of interest to declare.
Author contribution area and rate
Habib Erensoy prepared the abstract, statistical analysis, and discussion (100%).
| References|| |
Chisholm D, Sweeny K, Sheehan P, Rasmussen B, Smit F, Cuijpers P, et al
. Scaling-up treatment of depression and anxiety: A global return on investment analysis. Lancet Psychiatry 2016;3:415-24. doi: 10.1016/S2215-0366(16)30024-4.
Owen L, Corfe B. The role of diet and nutrition on mental health and wellbeing. Proc Nutr Soc 2017;76:425-6. doi: 10.1017/S0029665117001057.
Jacka FN. Nutritional psychiatry: Where to next? Ebio Med 2017;17:24-9. doi: 10.1016/j.ebiom.2017.02.020.
Coppen A, Bolander-Gouaille C. Treatment of depression: Time to consider folic acid and vitamin B12. J Psychopharmacol 2005;19:59-65. doi: 10.1177/0269881105048899.
Reynolds E. Vitamin B12, folic acid, and the nervous system. Lancet Neurol 2006;5:949-60. doi:10.1016/S1474-4422(06)70598-1.
Black MM. Effects of vitamin B12 and folate deficiency on brain development in children. Food Nutr Bull 2008;29:S126-31. doi: 10.1177/15648265080292S117.
Morris DW, Trivedi MH, Rush AJ. Folate and unipolar depression. J Alternat Complement Med 2008;14:277-85. doi: 10.1089/acm.2007.0663.
Papakostas GI, Petersen T, Mischoulon D, Green CH, Nierenberg AA, Bottiglieri T, et al
. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: Predictors of relapse during the continuation phase of pharmacotherapy. J Clin Psychiatry 2004;65:1096-8. doi: 10.4088/JCP.v65n0810.
Martínez-Cengotitabengoa M, González-Pinto A. Nutritional supplements in depressive disorders. Actas Esp Psiquiatr 2017;45:8-15.
Sepehrmanesh Z, Omidi A, Gholampoor N. Acid folic supplementation in major depressive disorder treatment: A double-blind randomized clinical trial. Iran Red Crescent Med J 2017;19:2:1-8:e33243. doi: 10.5812/ircmj.33243.
Walker JG, Mackinnon AJ, Batterham P, Jorm AF, Hickie I, McCarthy A, et al
. Mental health literacy, folic acid and vitamin B 12, and physical activity for the prevention of depression in older adults: Randomised controlled trial. Br J Psychiatry 2010;197:45-54. doi:10.1192/bjp.bp.109.075291.
Syed EU, Wasay M, Awan S. Vitamin B12 supplementation in treating major depressive disorder: A randomized controlled trial. Open Neurol J 2013;7:44-8. doi: 10.2174/1874205X01307010044.
Hintikka J, Tolmunen T, Tanskanen A, Viinamäki H. High vitamin B12 level and good treatment outcome may be associated in major depressive disorder. BMC Psychiatry 2003;3:17. doi: 10.1186/1471-244X-3-17.
Sachdev PS, Parslow RA, Lux O, Salonikas C, Wen W, Naidoo D, et al
. Relationship of homocysteine, folic acid and vitamin B12 with depression in a middle-aged community sample. Psychol Med 2005;35:529. doi: 10.1017/S0033291704003721.
De Koning EJ, van der Zwaluw NL, van Wijngaarden JP, Sohl E, Brouwer-Brolsma EM, van Marwijk HW, et al
. Effects of two-year vitamin B12 and folic acid supplementation on depressive symptoms and quality of life in older adults with elevated homocysteine concentrations: Additional results from the B-PROOF study, an RCT. Nutrients 2016;8:748. doi: 10.3390/nu8110748.
Adhikari PM, Chowta MN, Ramapuram JT, Rao SB, Udupa K, Acharya SD. Effect of vitamin B12 and folic acid supplementation on neuropsychiatric symptoms and immune response in HIV-positive patients. J Neurosci Rural Practice 2016;7:362. doi: 10.4103/0976-3147.182774.
Skarupski KA, Tangney C, Li H, Ouyang B, Evans DA, Morris MC. Longitudinal association of vitamin B-6, folate, and vitamin B-12 with depressive symptoms among older adults over time. Am J Clin Nutrit 2010;92:330-5. doi: 10.3945/ajcn.2010.29413.
Mustafa U, Sahin Nesrin H, Husnu E. Turkish version of the beck anxiety ınventory: Psychometric properties. J Cognit Psychother 1998;12:163-72.
Yildirim F, Ilhan IÖ. The validity and reliability of the general self-efficacy scale-Turkish form. Turk Psikiyatri Dergisi 2010;21:301.
Sánchez-Villegas A, Doreste J, Schlatter J, Pla J, Bes-Rastrollo M, Martínez-González M. Association between folate, vitamin B6 and vitamin B12 intake and depression in the SUN cohort study. J Human Nutrit Dietetics 2009;22:122-33. doi:10.1111/j.1365-277X.2008.00931.x.
Calderón-Ospina CA, Nava-Mesa MO. B Vitamins in the nervous system: Current knowledge of the biochemical modes of action and synergies of thiamine, pyridoxine, and cobalamin. CNS Neurosci Therapeut 2020;26:5-13. doi: 10.1111/cns.13207.
Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000;69:228-32. doi: 10.1136/jnnp.69.2.228.
Ford AH, Flicker L, Thomas J, Norman P, Jamrozik K, Almeida OP. Vitamins B12, B6, and folic acid for onset of depressive symptoms in older men: Results from a 2-year placebo-controlled randomized trial. J Clin Psychiatry 2008;69:1203-9. doi: 10.4088/jcp.v69n0801.
Lerner V, Kanevsky M, Dwolatzky T, Rouach T, Kamin R, Miodownik C. Vitamin B12 and folate serum levels in newly admitted psychiatric patients. Clin Nutrit 2006;25:60-7. doi: 10.1016/j.clnu.2005.08.014.
Margalit I, Cohen E, Goldberg E, Krause I. Vitamin B12 deficiency and the role of gender: A cross-sectional study of a large cohort. Ann Nutrit Metab 2018;72:265-71. doi: 10.1159/000488326.
Tanaka T, Scheet P, Giusti B, Bandinelli S, Piras MG, Usala G, et al
. Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. Am J Human Genetics 2009;84:477-82. doi: 10.1016/j.ajhg.2009.02.011.
Huang X, Fan Y, Han X, Huang Z, Yu M, Zhang Y, et al
. Association between serum vitamin levels and depression in US adults 20 years or older based on national health and nutrition examination survey 2005-2006. Int J Environ Res Public Health 2018;15:1215. doi: 10.3390/ijerph15061215.
Passen M, Cucinotta D, Abate G, Senin U, Ventura A, Badiale MS, et al
. Oral 5′-methyltetrahydrofolic acid in senile organic mental disorders with depression: Results of a double-blind multicenter study. Aging Clin Experim Res 1993;5:63-71. doi:10.1007/BF03324128.
Alpert JE, Mischoulon D, Rubenstein GE, Bottonari K, Nierenberg AA, Fava M. Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiatry 2002;14:33-8. doi:10.1023/A:1015271927517.
Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, et al
. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: Results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry 2012;169:1267-74. doi: 10.1176/appi.ajp.2012.11071114.
[Table 1], [Table 2], [Table 3], [Table 4]